01 8Azilva
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 689
2018 Revenue in Millions : 669
Growth (%) : 3
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 764
2019 Revenue in Millions : 703
Growth (%) : 9
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 670
2020 Revenue in Millions : 733
Growth (%) : -1
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 561
2021 Revenue in Millions : 670
Growth (%) : -16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 310
2022 Revenue in Millions : 561
Growth (%) : -38
Azilsartan Medoxomil Potassium
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 591
2015 Revenue in Millions : 519
Growth (%) : 14
Azilsartan Medoxomil Potassium
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 689
2016 Revenue in Millions : 631
Growth (%) : 9
Azilsartan Medoxomil Potassium
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 647
2017 Revenue in Millions : 646
Growth (%) : 0%
LOOKING FOR A SUPPLIER?